Eupraxia Pharmaceuticals Inc has seen a notable decline in its stock performance recently, with no major news to explain the downward trend.
Eupraxia Pharmaceuticals Inc (EPRX.TO) has experienced a challenging week, with its stock price down 11.42% over the past week. Despite a lack of significant news to drive this movement, the stock remains in focus for investors. Let's look at the latest performance metrics and technical indicators to understand the current landscape.
Investor takeaway: Investors should consider the recent stock performance and technical indicators of Eupraxia Pharmaceuticals as they navigate their investment decisions. With a strong implied analyst target, there may be potential for recovery, but caution is warranted given the company's current fundamentals.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$681.88M
52W high
$13.08
52W low
$7.35
1W change
-11.42%
Beta
1.49
Analyst Price Targets
Based on analyst covering EPRX · as of Sep 28, 2026
Wall Street analysts forecast EPRX stock price to rise 58.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.33
+58.3% Upside
Previously C$16.00 on Sep 17, 2026
Current Price
C$10.32
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
95.1%
Annualized
90-Day Vol
69.3%
Annualized
Trend (90d)
+21.7%
Annualized drift
90d Mean
C$11.15
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.59 | C$7.63 – C$14.70 |
| 60 trading days | C$10.87 | C$6.83 – C$17.29 |
| 90 trading days | C$11.15 | C$6.32 – C$19.69 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
C$10.99 Last Close
The stock has traded within a 52-week range of C$7.35 to C$13.08, indicating it is currently at 64% of its range, which may suggest volatility in its performance.
Bull case
Analysts are optimistic about Eupraxia Pharmaceuticals, with an average target of C$16.33, suggesting a potential upside of 48.6% from the current price. Positive clinical data and the recent transition to the Nasdaq could boost visibility and attract more investors.
Bear case
The company has faced a decline in stock price and has not reported significant recent news to counteract this trend. With a negative return on equity and a profit margin of 0.0%, there are concerns about its financial health and ability to generate sustainable growth.
Recent Price Action
Eupraxia Pharmaceuticals Inc (EPRX.TO) closed at C$10.99, marking a 1D change of 0.00%. Over the past week, the stock has seen a decline of 11.42%, while its month-to-date performance reflects a similar downturn of 11.34%. Year-to-date, the stock is down 1.34%, indicating a challenging period for investors.
Advertisement
Technical Picture
EPRX.TO's technical indicators show a last close of C$10.99, with a 50-day moving average of C$10.19 and a 200-day moving average of C$10.17, suggesting a slight upward trend in the short to medium term. The stock has a beta of 1.49, indicating higher volatility compared to the broader market. The latest trading volume was 116,946 shares, significantly above the 20-day average volume of 90,741 shares, indicating increased investor interest.
Insider Activity
No recent insider activity has been reported for Eupraxia Pharmaceuticals Inc, which may suggest stability in management and operations.
Analyst Outlook
Analysts maintain a bullish outlook for Eupraxia Pharmaceuticals, with an average target price of C$16.33, implying a potential upside of 48.6% from the current trading price. This optimistic view is supported by the company's recent clinical data and its transition to the Nasdaq Global Select Market, which may enhance its visibility among investors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
